Biosimilars and the long game

Trends in Biotechnology

Volumn 33, Issue 5, 2015, Pages 250-252

  Huzair, Farah ^a   Kale, Dinar ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b OPEN UNIVERSITY   (United Kingdom)

Author keywords

Biosimilar; Follow on biologic; Subsequent entry biologic

Indexed keywords

BIOSIMILAR AGENT; GENERIC DRUG;

DRUG INDUSTRY; HEALTH CARE COST; NOTE; PRIORITY JOURNAL; TECHNOLOGY; DRUG CONTROL; DRUG DESIGN; TRENDS;

BIOSIMILAR PHARMACEUTICALS; DRUG AND NARCOTIC CONTROL; DRUG DESIGN; DRUG INDUSTRY;

EID: 84928014582     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2015.01.001     Document Type: Note

References (10)

1. Huzair F., Kale D. Emergence of the Biosimilar Sector and Opportunities of Developing Country Suppliers 2011, Innogen.
2. Generics and Biosimilars Initiative (2014) Biosimilars Approved in Europe, GaBi. Published online November 14, 2014. http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe.
3. Editorial Building a wall against biosimilars. Nat. Biotechnol. 2013, 31:264.
4. What You Need to Know About Biosimilar Medicinal Products (Consensus Information Document) 2013, European Commission, European Commission.
5. Health Canada (2010) Questions and Answers To Accompany the Final Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs), Health Canada. Published online May 27, 2010. http://www.hc-sc.gc.ca/dhp-mps/brgtherap/applic-demande/guides/seb-pbu/01-2010-seb-pbu-qa-qr-eng.php.
6. US Food and Drug Administration (2014) Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations, FDA. Published online January 27, 2015. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm411418.htm.
7. Schneider C.K., Kalinke U. Toward biosimilar monoclonal antibodies. Nat. Biotechnol. 2008, 26:985-990.
8. European Medicines Agency (2013) Assessment Report: Remsima. International Non-Proprietary Name: Infliximab, EMA. Published online June 27, 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf.
9. Dorey, E. (2010) The next move in biopharma. Chemistry and Industry Magazine 24. Published online December 20, 2010. http://www.soci.org/Chemistry-and-Industry/CnI-Data/2010/24/The-next-move-in-biopharma.
10. Lee A., et al. Manufacturing strategies for biosimilars. Pharm. Technol. 2011, 35:36.